Recent investigations have centered on the intersection of GLP|GIP|glucagon receptor stimulant therapies and DA signaling. While GCGR stimulators are increasingly employed for addressing type 2 diabetes, their unexpected impacts on reinforcement circuits, specifically influenced by dopamine pathways, are receiving significant interest. This pape… Read More